Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Muhammad Furqan

Showing results (351-360 of 359) with videos related to

Pageof 36
Sort By:
You have reached the last page of results.This site can display upto 359 results.
Redox Biology|December 1, 2020
Magnetic resonance imaging (MRI) of pharmacological ascorbate-induced iron redox state as a biomarker in subjects undergoing radio-chemotherapyCameron M Cushing, Michael S Petronek, Kellie L Bodeker, et al.
Transboundary and Emerging Diseases|April 30, 2025
Migratory Wave due to Conflicts: Risk of Increased Infection From Zoonotic DiseasesSina Salajegheh Tazerji, Phelipe Magalhães Duarte, Rasha Gharieb, et al.
Redox Biology|May 7, 2022
Pharmacological ascorbate improves the response to platinum-based chemotherapy in advanced stage non-small cell lung cancerMuhammad Furqan, Taher Abu-Hejleh, Laura M Stephens, et al.
Immunity|April 18, 2024
Jagged2 targeting in lung cancer activates anti-tumor immunity via Notch-induced functional reprogramming of tumor-associated macrophagesJay K Mandula, Rosa A Sierra-Mondragon, Rachel V Jimenez, et al.
Nature Medicine|June 1, 2026
SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trialLauren Averett Byers, Byoung Chul Cho, Alissa J Cooper, et al.
Nature Medicine|June 29, 2026
Author Correction: SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trialLauren Averett Byers, Byoung Chul Cho, Alissa J Cooper, et al.
Cancer Cell|August 16, 2017
O<sub>2</sub><sup>⋅-</sup> and H<sub>2</sub>O<sub>2</sub>-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological AscorbateJoshua D Schoenfeld, Zita A Sibenaller, Kranti A Mapuskar, et al.
Cancer Cell|April 4, 2017
O<sub>2</sub><sup>⋅-</sup> and H<sub>2</sub>O<sub>2</sub>-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological AscorbateJoshua D Schoenfeld, Zita A Sibenaller, Kranti A Mapuskar, et al.
Translational Lung Cancer Research|November 4, 2021
Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancerBin Qiu, Kaican Cai, Chun Chen, et al.
Pageof 36

Showing results (351-360 of 359) with videos related to

Sort By:
Pageof 36
You have reached the last page of results.This site can display upto 359 results.
Redox Biology|December 1, 2020
Magnetic resonance imaging (MRI) of pharmacological ascorbate-induced iron redox state as a biomarker in subjects undergoing radio-chemotherapyCameron M Cushing, Michael S Petronek, Kellie L Bodeker, et al.
Transboundary and Emerging Diseases|April 30, 2025
Migratory Wave due to Conflicts: Risk of Increased Infection From Zoonotic DiseasesSina Salajegheh Tazerji, Phelipe Magalhães Duarte, Rasha Gharieb, et al.
Redox Biology|May 7, 2022
Pharmacological ascorbate improves the response to platinum-based chemotherapy in advanced stage non-small cell lung cancerMuhammad Furqan, Taher Abu-Hejleh, Laura M Stephens, et al.
Immunity|April 18, 2024
Jagged2 targeting in lung cancer activates anti-tumor immunity via Notch-induced functional reprogramming of tumor-associated macrophagesJay K Mandula, Rosa A Sierra-Mondragon, Rachel V Jimenez, et al.
Nature Medicine|June 1, 2026
SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trialLauren Averett Byers, Byoung Chul Cho, Alissa J Cooper, et al.
Nature Medicine|June 29, 2026
Author Correction: SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trialLauren Averett Byers, Byoung Chul Cho, Alissa J Cooper, et al.
Cancer Cell|August 16, 2017
O<sub>2</sub><sup>⋅-</sup> and H<sub>2</sub>O<sub>2</sub>-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological AscorbateJoshua D Schoenfeld, Zita A Sibenaller, Kranti A Mapuskar, et al.
Cancer Cell|April 4, 2017
O<sub>2</sub><sup>⋅-</sup> and H<sub>2</sub>O<sub>2</sub>-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological AscorbateJoshua D Schoenfeld, Zita A Sibenaller, Kranti A Mapuskar, et al.
Translational Lung Cancer Research|November 4, 2021
Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancerBin Qiu, Kaican Cai, Chun Chen, et al.
Pageof 36